Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Thyro-Block, Potassium Iodide, Iosat. Every FDA application for this active ingredient: 3 branded and 3 generic.
As of Nov 15, 2026, FDA lists 6 applications for Potassium Iodide (sold as Thyro-Block, Potassium Iodide, Iosat), first approved Nov 9, 1979, with 0 new uses approved and 0 published complete response letters.
Potassium Iodide PillsA drug with a new additional indication and a new dosage for the prevention and reduction of internal exposure to radioactive iodine in the thyroid gland. · Nichi-Iko Pharmaceutical Co., Ltd. · Apr 30, 2013
Clinical Trials
14 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Roxane